Analyst Reco. Cara Therapeutics, Inc.

Equities

CARA

US1407551092

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.6843 ^USD	-2.24%		+3.52%	-7.90%

Mar. 22	Cara Therapeutics, Inc. Announces Resignation of Dr. Joana Goncalves as Chief Medical Officer, Effective April 16, 2024	CI
Mar. 06	Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating	Mar. 06	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $2.50 From $7, Keeps Buy Rating	Dec. 19	MT
Needham Adjusts Price Target on Cara Therapeutics to $6 From $22, Maintains Buy Rating	Dec. 18	MT
Piper Sandler Downgrades Cara Therapeutics to Neutral From Overweight, Cuts Price Target to $1 From $12	Nov. 14	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $7 From $15, Keeps Buy Rating	23-10-19	MT
HC Wainwright Lowers Price Target on Cara Therapeutics to $15 From $20, Maintains Buy Rating	23-05-16	MT
BofA Securities Adjusts Price Target on Cara Therapeutics to $4 From $6, Maintains Underperform Rating	23-05-16	MT
BofA Securities Downgrades Cara Therapeutics to Underperform From Neutral, Cuts PT to $6 From $13 on Lower Peak Sales Forecast of Drug	23-03-08	MT
BofA Downgrades Cara Therapeutics to Underperform From Neutral, Adjusts Price Target to $6 From $13	23-03-08	MT
Canaccord Genuity Adjusts Price Target on Cara Therapeutics to $25 From $29, Maintains Buy Rating	23-03-07	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $20 From $25, Keeps Buy Rating	23-03-07	MT
Piper Sandler Adjusts Price Target on Cara Therapeutics to $13 From $25, Keeps Overweight Rating	23-03-07	MT
JPMorgan Adjusts Price Target on Cara Therapeutics to $16 From $19, Maintains Overweight Rating	23-03-07	MT
Needham Cuts Price Target on Cara Therapeutics to $22 From $26, Maintains Buy Rating	23-03-07	MT
HC Wainwright Adjusts Price Target on Cara Therapeutics to $25 From $30, Maintains Buy Rating	23-02-14	MT
Canaccord Genuity Adjusts Cara Therapeutics' Price Target to $29 from $33, Keeps Buy Rating	22-03-14	MT
HC Wainwright Adjusts Cara Therapeutics' Price Target to $30 from $35, Keeps Buy Rating	22-03-14	MT
JPMorgan Raises Cara Therapeutics to Overweight From Neutral, Price Target to $20 From $17	22-03-08	MT
CARA THERAPEUTICS : HC Wainwright Adjusts Price Target on Cara Therapeutics to $35 From $33, Maintains Buy Rating	21-08-24	MT
CARA THERAPEUTICS : JPMorgan Starts Cara Therapeutics at Neutral With $16 Price Target	21-08-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Cara Therapeutics, Inc.

Equities

CARA

US1407551092

Analyst Reco.

Filters